Gene: SLC6A2

6530
NAT1|NET|NET1|SLC6A5
solute carrier family 6 member 2
protein-coding
16q12.2
Ensembl:ENSG00000103546 MIM:163970 Vega:OTTHUMG00000133208 UniprotKB:P23975
NG_016969.1
PubMed
ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.448e-1 (AD)  4.823e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FAM216B0.573
VIP0.565
IGF10.564
NPR30.55
THSD7A0.541
ADAMTS50.533
CHRNA60.529
SSTR40.528
PTHLH0.527
RELN0.527

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AQP1-0.385
KIF19-0.374
PLEKHF1-0.374
TFEB-0.35
NKX6-2-0.349
TK1-0.347
RTKN-0.345
CRYAA-0.343
ANKRD23-0.342
TGFB3-0.342

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00215CitalopramSmall Molecule59729-33-8ApprovedTransporter
DB00368NorepinephrineSmall Molecule51-41-2ApprovedTransporter
DB01454MidomafetamineSmall Molecule42542-10-9Experimental|Illicit|InvestigationalTransporter
DB06262DroxidopaSmall Molecule23651-95-8Approved|InvestigationalTransporter
DB06704IobenguaneSmall Molecule80663-95-2Approved|InvestigationalTransporter
DB09194EtoperidoneSmall Molecule52942-31-1WithdrawnTransporter
DB09363Rauwolfia serpentina rootSmall Molecule8063-17-0InvestigationalTransporter
DB09546Iobenguane sulfate I-123Small Molecule80663-95-2Approved|InvestigationalTransporter
DB00182AmphetamineSmall Molecule300-62-9Approved|Illicit|InvestigationalTarget
DB00191PhentermineSmall Molecule122-09-8Approved|IllicitTarget
DB00193TramadolSmall Molecule27203-92-5Approved|InvestigationalTarget
DB00226GuanadrelSmall Molecule40580-59-4ApprovedTarget
DB00234ReboxetineSmall Molecule71620-89-8Approved|InvestigationalTarget
DB00285VenlafaxineSmall Molecule93413-69-5ApprovedTarget
DB00289AtomoxetineSmall Molecule83015-26-3ApprovedTarget
DB00321AmitriptylineSmall Molecule50-48-6ApprovedTarget
DB00344ProtriptylineSmall Molecule438-60-8ApprovedTarget
DB00370MirtazapineSmall Molecule85650-52-8ApprovedTarget
DB00408LoxapineSmall Molecule1977-10-2ApprovedTarget
DB00422MethylphenidateSmall Molecule113-45-1Approved|InvestigationalTarget
DB00454PethidineSmall Molecule57-42-1ApprovedTarget
DB00458ImipramineSmall Molecule50-49-7ApprovedTarget
DB00476DuloxetineSmall Molecule116539-59-4ApprovedTarget
DB00514DextromethorphanSmall Molecule125-71-3ApprovedTarget
DB00540NortriptylineSmall Molecule72-69-5ApprovedTarget
DB00543AmoxapineSmall Molecule14028-44-5ApprovedTarget
DB00579MazindolSmall Molecule22232-71-9Approved|InvestigationalTarget
DB00696ErgotamineSmall Molecule113-15-5ApprovedTarget
DB00715ParoxetineSmall Molecule61869-08-7Approved|InvestigationalTarget
DB00726TrimipramineSmall Molecule739-71-9ApprovedTarget
DB00830PhenmetrazineSmall Molecule134-49-6Approved|IllicitTarget
DB00852PseudoephedrineSmall Molecule90-82-4ApprovedTarget
DB00907CocaineSmall Molecule50-36-2Approved|IllicitTarget
DB00934MaprotilineSmall Molecule10262-69-8Approved|InvestigationalTarget
DB00937DiethylpropionSmall Molecule90-84-6Approved|IllicitTarget
DB00988DopamineSmall Molecule51-61-6ApprovedTarget
DB01105SibutramineSmall Molecule106650-56-0Approved|Illicit|Investigational|WithdrawnTarget
DB01114ChlorphenamineSmall Molecule132-22-9ApprovedTarget
DB01142DoxepinSmall Molecule1668-19-5Approved|InvestigationalTarget
DB01149NefazodoneSmall Molecule83366-66-9Approved|WithdrawnTarget
DB01151DesipramineSmall Molecule50-47-5Approved|InvestigationalTarget
DB01156BupropionSmall Molecule34911-55-2ApprovedTarget
DB01170GuanethidineSmall Molecule55-65-2ApprovedTarget
DB01173OrphenadrineSmall Molecule83-98-7ApprovedTarget
DB01175EscitalopramSmall Molecule128196-01-0Approved|InvestigationalTarget
DB01221KetamineSmall Molecule6740-88-1ApprovedTarget
DB01242ClomipramineSmall Molecule303-49-1Approved|InvestigationalTarget
DB01363EphedraSmall Molecule-Approved|Nutraceutical|WithdrawnTarget
DB01364EphedrineSmall Molecule299-42-3ApprovedTarget
DB01381Ginkgo bilobaSmall Molecule-Approved|Investigational|NutraceuticalTarget
DB01442MMDASmall Molecule13674-05-0Experimental|IllicitTarget
DB01454MidomafetamineSmall Molecule42542-10-9Experimental|Illicit|InvestigationalTarget
DB01576DextroamphetamineSmall Molecule51-64-9Approved|IllicitTarget
DB01577MethamphetamineSmall Molecule537-46-2Approved|IllicitTarget
DB01579PhendimetrazineSmall Molecule634-03-7Approved|IllicitTarget
DB04821NomifensineSmall Molecule24526-64-5WithdrawnTarget
DB04836AmineptineSmall Molecule57574-09-1Illicit|WithdrawnTarget
DB04840DebrisoquinSmall Molecule1131-64-2Approved|InvestigationalTarget
DB04889BicifadineSmall Molecule71195-57-8InvestigationalTarget
DB04896MilnacipranSmall Molecule92623-85-3Approved|InvestigationalTarget
DB05012XEN2174Small Molecule-InvestigationalTarget
DB05642DDP-225Small Molecule476148-82-0InvestigationalTarget
DB05688CRx-119Small Molecule-InvestigationalTarget
DB06148MianserinSmall Molecule24219-97-4Approved|InvestigationalTarget
DB06156TesofensineSmall Molecule195875-84-4InvestigationalTarget
DB06204TapentadolSmall Molecule175591-23-8ApprovedTarget
DB06333TrodusquemineBiotechDrug186139-09-3InvestigationalTarget
DB06700DesvenlafaxineSmall Molecule93413-62-8Approved|InvestigationalTarget
DB06701DexmethylphenidateSmall Molecule40431-64-9Approved|InvestigationalTarget
DB08918LevomilnacipranSmall Molecule96847-54-0Approved|InvestigationalTarget
DB09167DosulepinSmall Molecule113-53-1ApprovedTarget
DB09185ViloxazineSmall Molecule46817-91-8Approved|Investigational|WithdrawnTarget
DB09225ZotepineSmall Molecule26615-21-4Approved|Investigational|WithdrawnTarget
DB12305DasotralineSmall Molecule675126-05-3InvestigationalTarget
ID Drug Name Action PubMed
C5685141-(2-fluorophenyl)-3-(2-(morpholin-2-yl)ethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide"1-(2-fluorophenyl)-3-(2-(morpholin-2-yl)ethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide binds to and results in decreased activity of SLC6A2 protein"21916421
C0005922731-phenyl-2-(1-pyrrolidinyl)-1-pentanone1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
C0005922731-phenyl-2-(1-pyrrolidinyl)-1-pentanone1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC6A2 mRNA"25510870
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of SLC6A2 mRNA"27291303
C5691132-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
C5691132-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC6A2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC6A2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC6A2 mRNA"25510870
C0793212-(4-bromo-2,5-dimethoxyphenyl)ethylamine"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
C0793212-(4-bromo-2,5-dimethoxyphenyl)ethylamine"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
C0005959262-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
C0005959262-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
C5541812-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
C5541812-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
C4086042-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Cocaine results in increased expression of and results in increased phosphorylation of SLC6A2 protein]25724654
C4086042-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole results in decreased phosphorylation of SLC6A2 protein25724654
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC6A2 mRNA"25510870
C5499132-((8-chlorodibenzo(b,f)thiepin-10-yl)oxy)-N-methylethan-1-amine"2-((8-chlorodibenzo(b,f)thiepin-10-yl)oxy)-N-methylethan-1-amine results in decreased activity of SLC6A2 protein"20223878
C0406394-fluoroamphetamine4-fluoroamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
C0406394-fluoroamphetamine4-fluoroamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
C0601694-methoxymethamphetamine4-methoxymethamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
C0601694-methoxymethamphetamine4-methoxymethamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
C0006082505-(2-aminopropyl)benzofuran5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
C0006082505-(2-aminopropyl)benzofuran5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D000643Ammonium ChlorideAmmonium Chloride affects the expression of SLC6A2 mRNA16483693
D003913DextroamphetamineSLC6A2 gene SNP affects the susceptibility to Dextroamphetamine17239355
D000661AmphetamineAmphetamine inhibits the reaction [nisoxetine binds to SLC6A2 protein]11082428
D000661AmphetamineAmphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D000661AmphetamineAmphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D000661AmphetamineAmphetamine results in decreased activity of SLC6A2 protein11082428
D000661AmphetamineAmphetamine results in decreased expression of SLC6A2 protein11082428
D000661AmphetamineSLC6A2 SNP affects the susceptibility to Amphetamine19727679
D001151ArsenicArsenic results in decreased expression of SLC6A2 mRNA19654921
C006632arsenic trioxideSLC6A2 protein results in decreased susceptibility to arsenic trioxide20707922
C487081belinostatbelinostat results in increased expression of SLC6A2 mRNA27188386
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of SLC6A2 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SLC6A2 mRNA21569818|2222880
D015306Biogenic Monoamines1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic Monoamines2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic Monoamines"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
D015306Biogenic Monoamines"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
D015306Biogenic Monoamines"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
D015306Biogenic Monoamines4-fluoroamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic Monoamines4-methoxymethamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic Monoamines5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic MonoaminesAmphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic MonoaminesCocaine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic MonoaminesFluoxetine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D015306Biogenic Monoamines"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
D015306Biogenic MonoaminesSLC6A2 protein results in increased import of Biogenic Monoamines analog28506818
C006780bisphenol Abisphenol A results in decreased expression of SLC6A2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of SLC6A2 gene28505145
D002045BupivacaineBupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of SLC6A2 mRNA12734012
D002330CarmustineCarmustine results in increased expression of SLC6A2 mRNA15980968
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein24394491
D020111Chlorodiphenyl (54% Chlorine)[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]24394491
D002737ChloropreneChloroprene results in increased expression of SLC6A2 mRNA23125180
D004390ChlorpyrifosChlorpyrifos affects the expression of SLC6A2 mRNA17452286
D004390ChlorpyrifosChlorpyrifos results in increased expression of SLC6A2 mRNA18812211
D003024ClozapineClozapine results in decreased activity of SLC6A2 protein11359867
D003024ClozapineClozapine results in increased activity of SLC6A2 protein11359867
D003024ClozapineClozapine results in increased expression of SLC6A2 mRNA11359867
D003024ClozapineCycloheximide inhibits the reaction [Clozapine results in increased activity of SLC6A2 protein]11359867
D003024ClozapineDactinomycin inhibits the reaction [Clozapine results in increased activity of SLC6A2 protein]11359867
D003024ClozapineClozapine results in decreased expression of SLC6A2 mRNA18923069
D003042CocaineCocaine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D003042CocaineCocaine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D003042CocaineCocaine results in decreased activity of SLC6A2 protein11082428
D003042CocaineCocaine results in increased expression of SLC6A2 protein15763139|1972836
D003042Cocaine2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Cocaine results in increased expression of and results in increased phosphorylation of SLC6A2 protein]25724654
D003042CocaineCocaine results in increased expression of SLC6A2 protein25724654
D003042CocaineCocaine results in increased phosphorylation of SLC6A2 protein25724654
D003042CocaineSB 203580 inhibits the reaction [Cocaine results in increased expression of SLC6A2 protein]25724654
D003042CocaineSLC6A2 protein results in increased susceptibility to Cocaine15911120
D003300Copper[Copper co-treated with Dietary Sucrose] results in increased expression of SLC6A2 mRNA26033743
D003300CopperCopper deficiency results in increased expression of SLC6A2 mRNA26033743
D019327Copper SulfateCopper Sulfate results in increased expression of SLC6A2 mRNA19549813
D003513CycloheximideCycloheximide inhibits the reaction [Clozapine results in increased activity of SLC6A2 protein]11359867
C532102D-161 compoundD-161 compound results in decreased activity of SLC6A2 protein18561912
D003609DactinomycinDactinomycin inhibits the reaction [Clozapine results in increased activity of SLC6A2 protein]11359867
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of SLC6A2 mRNA23640034
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of SLC6A2 mRNA23914054
D003676DeferoxamineDeferoxamine results in decreased expression of SLC6A2 protein16650837
D003891DesipramineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]17234900
D003891DesipramineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]17234900
D003891DesipramineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]17234900
D003891DesipramineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]17234900
D003891DesipramineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]17234900
D003891DesipramineBupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D003891Desipramine[Desipramine binds to and results in decreased activity of SLC6A2 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium20079841
D003891DesipramineDesipramine results in decreased activity of SLC6A2 protein19616025
D003891Desipramine[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine16725121
D003891DesipramineDesipramine results in decreased expression of SLC6A2 protein18923402
D003891DesipramineLidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D003891Desipraminetricaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D003891DesipramineDesipramine results in decreased activity of SLC6A2 protein18561912
D003891DesipramineDesipramine results in decreased activity of SLC6A2 protein16725121|2007984
D004026DieldrinDieldrin affects the expression of SLC6A2 mRNA18812211
D019422Dietary Sucrose[Copper co-treated with Dietary Sucrose] results in increased expression of SLC6A2 mRNA26033743
D019422Dietary SucroseDietary Sucrose results in increased expression of SLC6A2 mRNA26033743
D004298DopamineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]17234900
D004298Dopamineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]17234900
D004298DopamineSLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]17234900
D004298DopamineSLC6A2 protein results in increased uptake of Dopamine20626558
D005419FlavonoidsFlavonoids results in increased expression of SLC6A2 mRNA18035473
D005456Fluorescent Dyes1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent Dyes2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent Dyes"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
D005456Fluorescent Dyes"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
D005456Fluorescent Dyes"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
D005456Fluorescent Dyes4-fluoroamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent Dyes4-methoxymethamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent Dyes5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent DyesAmphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent DyesCocaine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent DyesFluoxetine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D005456Fluorescent Dyes"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
D005456Fluorescent DyesSLC6A2 protein results in increased import of Fluorescent Dyes28506818
D005473FluoxetineFluoxetine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]28506818
D005473FluoxetineFluoxetine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]28506818
D004397FonofosFonofos results in increased methylation of SLC6A2 promoter22847954
C097367ginsenoside Rg3[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]24394491
D012701SerotoninSLC6A2 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]17234900
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A2 mRNA17183730
C029424hydrazinehydrazine results in decreased expression of SLC6A2 mRNA15282401
C418119indatralineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]17234900
C418119indatralineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]17234900
C418119indatralineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]17234900
C418119indatralineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]17234900
C418119indatralineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]17234900
D007608Kainic AcidSLC6A2 protein results in increased susceptibility to Kainic Acid15911120
D007649Ketamine[Ketamine co-treated with Xylenes] results in decreased activity of SLC6A2 protein17934728
D007649KetamineKetamine results in decreased activity of SLC6A2 protein17934728
D007854LeadLead results in decreased expression of SLC6A2 mRNA19921347
C008261lead acetatelead acetate affects the expression of SLC6A2 mRNA21864555
D008012LidocaineLidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D008344Maneb[Paraquat co-treated with Maneb] affects the expression of SLC6A2 mRNA22563483
D008694MethamphetamineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]17234900
D008694Methamphetamineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]17234900
D008694MethamphetamineSLC6A2 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]17234900
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]"28506818
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]"28506818
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium affects the expression of SLC6A2 mRNA12710931
D0156551-Methyl-4-phenylpyridinium[Desipramine binds to and results in decreased activity of SLC6A2 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium20079841
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in decreased expression of SLC6A2 mRNA22401849
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of SLC6A2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon analog affects the expression of SLC6A2 mRNA"25554681
D009532NickelNickel results in decreased expression of SLC6A2 mRNA24768652|2558310
D009532NickelNickel results in decreased expression of SLC6A2 mRNA18812211
C011386nisoxetineAmphetamine inhibits the reaction [nisoxetine binds to SLC6A2 protein]11082428
C011386nisoxetineNorepinephrine inhibits the reaction [nisoxetine binds to SLC6A2 protein]11082428
C011386nisoxetinenisoxetine results in decreased activity of SLC6A2 protein17505018
D009638NorepinephrineNorepinephrine inhibits the reaction [nisoxetine binds to SLC6A2 protein]11082428
D009638NorepinephrineNorepinephrine results in decreased activity of SLC6A2 protein11082428
D009638NorepinephrineNorepinephrine results in decreased expression of SLC6A2 protein11082428
D009638NorepinephrineSLC6A2 mutant form results in decreased uptake of Norepinephrine11458707
D009638NorepinephrineSLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]17234900
D009638NorepinephrineSLC6A2 protein affects the transport of Norepinephrine11223167
D009638NorepinephrineSLC6A2 protein alternative form results in decreased transport of Norepinephrine11223167
D009638NorepinephrineBupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D009638Norepinephrine[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine16725121
D009638NorepinephrineLidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D009638Norepinephrinetricaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
D009638NorepinephrineNorepinephrine affects the localization of and affects the metabolism of SLC6A2 protein16338971
D009661NortriptylineSLC6A2 gene polymorphism affects the susceptibility to Nortriptyline17018806
D009655OctopamineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]17234900
D009655Octopamineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]17234900
D009655OctopamineSLC6A2 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]17234900
D010269Paraquat[Paraquat co-treated with Maneb] affects the expression of SLC6A2 mRNA22563483
D010278ParathionParathion results in increased methylation of SLC6A2 promoter22847954
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SLC6A2 mRNA"25510870
D010433PentylenetetrazoleSLC6A2 protein results in increased susceptibility to Pentylenetetrazole15911120
C029261phenethylamineSLC6A2 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein]17234900
D010795Phthalic AcidsPhthalic Acids results in decreased expression of SLC6A2 mRNA21061450
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SLC6A2 mRNA19710929
D010936Plant ExtractsPlant Extracts results in decreased expression of SLC6A2 mRNA23557933
D010936Plant Extracts[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]24394491
D011374ProgesteroneProgesterone results in decreased expression of SLC6A2 mRNA23012394
D011530ProtriptylineProtriptyline results in decreased expression of SLC6A2 protein18923402
C074679reboxetinereboxetine results in decreased expression of SLC6A2 protein18923402
C074679reboxetinereboxetine results in decreased activity of SLC6A2 protein18259012
D012110ReserpineReserpine results in decreased expression of SLC6A2 mRNA7478180|7616203
C093642SB 203580SB 203580 inhibits the reaction [Cocaine results in increased expression of SLC6A2 protein]25724654
D012643SeleniumSelenium results in decreased expression of SLC6A2 mRNA19244175
D053260SootSoot results in increased expression of SLC6A2 mRNA26551751
C001750talsupramtalsupram results in decreased activity of SLC6A2 protein17505018
C012568terbufosterbufos results in increased methylation of SLC6A2 promoter22847954
D013729Terpenes[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]24394491
C009495titanium dioxidetitanium dioxide results in decreased expression of SLC6A2 mRNA23557971
C003636tricainetricaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]16725121
C030820tryptamineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]17234900
C030820tryptamineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]17234900
C030820tryptamineSLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]17234900
D014439TyramineDesipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]17234900
D014439Tyramineindatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]17234900
D014439TyramineSLC6A2 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]17234900
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A2 mRNA17183730
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of SLC6A2 gene25560391
C025643vinclozolinvinclozolin results in decreased expression of SLC6A2 mRNA23869203
D014810Vitamin EVitamin E results in decreased expression of SLC6A2 mRNA19244175
D014992Xylenes[Ketamine co-treated with Xylenes] results in decreased activity of SLC6A2 protein17934728
D014992XylenesXylenes results in decreased activity of SLC6A2 protein17934728
D015215ZidovudineZidovudine results in increased expression of SLC6A2 mRNA24292225
D019287Zinc SulfateZinc Sulfate results in increased expression of SLC6A2 mRNA16330358

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003779actin binding-IPI18331289  
GO:0005215transporter activity-IBA21873635  
GO:0005328neurotransmitter:sodium symporter activity-IEA-  
GO:0005330dopamine:sodium symporter activity-IBA21873635  
GO:0005333norepinephrine transmembrane transporter activity-IBA21873635  
GO:0005334norepinephrine:sodium symporter activity-TAS-  
GO:0005515protein binding-IPI11343649  17156375  18331289  
GO:0008504monoamine transmembrane transporter activity-IDA16024787  
GO:0043014alpha-tubulin binding-IEA-  
GO:0046872metal ion binding-IEA-  
GO:0048487beta-tubulin binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007268chemical synaptic transmission-TAS2008212  
GO:0015844monoamine transport-IDA16024787  
GO:0015874norepinephrine transport-IBA21873635  
GO:0035725sodium ion transmembrane transport-IBA21873635  
GO:0035725sodium ion transmembrane transport-IEA-  
GO:0048265response to pain-IEA-  
GO:0051583dopamine uptake involved in synaptic transmission-IBA21873635  
GO:0070050neuron cellular homeostasis-TAS18331289  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-TAS-  
GO:0009986cell surface-IEA-  
GO:0016020membrane-TAS2008212  
GO:0032809neuronal cell body membrane-IBA21873635  
GO:0042734presynaptic membrane-IBA21873635  
GO:0043005neuron projection-IBA21873635  
GO:0045121membrane raft-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1643685DiseaseTAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-425366Transport of bile salts and organic acids, metal ions and amine compoundsTAS
R-HSA-425407SLC-mediated transmembrane transportTAS
R-HSA-442660Na+/Cl- dependent neurotransmitter transportersTAS
R-HSA-5619102SLC transporter disordersTAS
R-HSA-5619109Defective SLC6A2 causes orthostatic intolerance (OI)TAS
R-HSA-5619115Disorders of transmembrane transportersTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21070505Multiple polymorphisms in genes of the adrenergic stress system confer vulnerability to alcohol abuse. (2012 Jan)Clarke TKAddict Biol
29032150Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. (2018 Jan 30)Sundararajan TGene
23185385Comprehensive phenotype/genotype analyses of the norepinephrine transporter gene (SLC6A2) in ADHD: relation to maternal smoking during pregnancy. (2012)Thakur GAPLoS One